1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)

MLA

P. Schuett, et al. “1244P Durvalumab after Definitive Radiochemotherapy (RCT) in Locally Advanced Unresectable NSCLC: Real-World Data on Survival and Safety from the German Expanded Access Program (EAP).” Annals of Oncology, vol. 31, Sept. 2020, pp. S806–07. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.117.

APA

P. Schuett, F. Steger, M. Faehling, S. Eisenmann, M. Horn, S. Sackmann, Petra Hoffknecht, A. Schlenska-Lange, Petros Christopoulos, Daniel C. Christoph, S.P. Aries, Christian Schumann, & Jürgen Alt. (2020). 1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). Annals of Oncology, 31, S806–S807. https://doi.org/10.1016/j.annonc.2020.08.117

Chicago

P. Schuett, F. Steger, M. Faehling, S. Eisenmann, M. Horn, S. Sackmann, Petra Hoffknecht, et al. 2020. “1244P Durvalumab after Definitive Radiochemotherapy (RCT) in Locally Advanced Unresectable NSCLC: Real-World Data on Survival and Safety from the German Expanded Access Program (EAP).” Annals of Oncology 31 (September): S806–7. doi:10.1016/j.annonc.2020.08.117.